A growth-oriented biopharmaceutical company improving patient lives by developing and commercializing advanced products across a range of therapies.

Addressing today’s medical challenges with a diversified portfolio of innovative products and partnerships.

products

We believe that our products have the potential to impact people's lives.

Read more

Gvoke ®

(glucagon injection)

Gvoke HypoPen® is the first FDA-approved autoinjector for very low blood sugar that is premixed and ready-to-use. It is a prescription medicine used to treat very low blood sugar (severe hypoglycemia) in adults and children ages 2 years and above with diabetes. It is available in both pediatric (0.5mg/0.1mL) and adult (1.0mg/0.2mL) doses.

Learn more

Keveyis ®

(dichlorphenamide)

KEVEYIS is the first and only FDA-approved treatment for Primary Periodic Paralysis. It is a prescription drug used to treat primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and other similar diseases. Keveyis has been shown to reduce the number, severity, and duration of Primary Periodic Paralysis attacks.

Learn more

Recorlev ®

(levoketoconazole)

Recorlev is a cortisol synthesis inhibitor indicated for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative.

Please see Important Safety Information, including boxed warning, and Full Prescribing Information

Learn more

product pipeline

Xeris has developed a robust pipeline of development programs for extending currently marketed products into important new indications and uses. Our pipeline also launches new products utilizing our proprietary formulation technology platforms to support long-term product development and commercial success.

Pipeline includes products across the range of development

Product Candidate
Indication
Pre-Clinical
Phase 1
Phase 2
Phase 3
Marketed
Gvoke® (US) (glucagon injection)
Severe Hypoglycemia info
 
PreClinical
 
Phase 1
 
Phase 2
 
Phase 3
 
Marketed

Severe hypoglycemia, or severe low blood sugar, occurs when your blood sugar gets so low that you need help to bring it back up. Sometimes people with very low blood sugar may have a hard time thinking straight or controlling their body, get very tired, refuse to eat, pass out, or even have a seizure. It is an emergency situation that needs to be treated immediately.*

*National Institute of Diabetes and Digestive and Kidney Diseases. Hypoglycemia. https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/low-blood-glucose-hypoglycemia. Published July 2021.

Keveyis® (dichlorphenamide)
Primary Periodic Paralysis†
 
PreClinical
 
Phase 1
 
Phase 2
 
Phase 3
 
Marketed

Primary Periodic Paralysis (PPP) is a rare genetic condition that affects muscles and causes episodes of muscle weakness and/or temporary paralysis, that can be progressive and debilitating. 1,2

1 Statland JM, Fontaine B, Hanna MG, et al. Review of the diagnosis and treatment of periodic paralysis. Muscle Nerve. 2018;57:522-530.
2 Cavel-Greant D, Lehmann-Horn F, Jurkat-Rott K. The impact of permanent muscle weakness on quality of life in periodic paralysis: a survey of 66 patients. Acta Myol. 2012;31:126-133.

Ogluo® (EU)** (glucagon)
Severe Hypoglycemia
 
PreClinical
 
Phase 1
 
Phase 2
 
Phase 3
 
Marketed

Severe hypoglycemia, or severe low blood sugar, occurs when your blood sugar gets so low that you need help to bring it back up. Sometimes people with very low blood sugar may have a hard time thinking straight or controlling their body, get very tired, refuse to eat, pass out, or even have a seizure. It is an emergency situation that needs to be treated immediately. *

*National Institute of Diabetes and Digestive and Kidney Diseases. Hypoglycemia. https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/low-blood-glucose-hypoglycemia. Published July 2021.

Recorlev® (levoketoconazole)
Endogenous Cushing's Syndrome†
 
PreClinical
 
Phase 1
 
Phase 2
 
Phase 3
 
Marketed

Endogenous CS is a rare, serious endocrine disorder caused by chronic exposure to elevated levels of cortisol; left untreated, it can be fatal. Often the result of a benign tumor of the pituitary gland that tells the body to overproduce high levels of cortisol for a sustained period of time. CS results in physical and emotional signs and symptoms that are debilitating for those living with CS. It is most common among adults aged 30 to 50 years and is more prevalent in females, accounting for 70% of cases.*

* The National Institute of Diabetes and Digestive and Kidney Diseases Health Information Center. Cushing’s Syndrome. Accessed Sept. 14, 2020. https://www.niddk.nih.gov/health-information/endocrine-diseases/cushings-syndrome.

Self-Administered Glucagon for Prevention
Exercise-Associated Hypoglycemia
 
PreClinical
 
Phase 1
 
Phase 2
 
Phase 3
 
Marketed

Exercise-Associated Hypoglycemia is characterized by a sudden and exaggerated spike in insulin and drop in blood sugar levels. The condition is triggered by vigorous exercise. Signs and symptoms include fainting (syncope),1 shakiness, nervousness, sweating, dizziness or light-headedness, sleepiness, confusion, difficulty speaking, anxiety, and weakness.2

1. Hyperinsulinemic hypoglycemia, familial, 7; HHF7. OMIM. November 2008; http://omim.org/entry/610021. Accessed 12/4/2013.
2. Hypoglycemia. NIDDK. November 6, 2012; https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/low-blood-glucose-hypoglycemia. Accessed 12/4/2013.

Levothyroxine
Endocrinology: Hypothyroidism
 
PreClinical
 
Phase 1
 
Phase 2
 
Phase 3
 
Marketed

Hypothyroidism, also known as underactive thyroid disease, is a condition in which the thyroid gland does not create and release enough thyroid hormone into the bloodstream. Hypothyroidism may not cause noticeable symptoms in the early stages. Over time, untreated hypothyroidism can cause a number of health problems, such as obesity, joint pain, infertility, and heart disease. Hypothyroidism is a fairly common condition that can affect people of all ages, genders, and ethnicities.

XP-9164
Gastroenterology
 
PreClinical
 
Phase 1
 
Phase 2
 
Phase 3
 
Marketed

Gastroenterology is a branch of medicine concerned with digestive diseases. The practice of gastroenterology concentrates on the diagnosis and treatment of diseases involving the esophagus, stomach, small intestine and large intestine (colon), liver, gallbladder, and pancreas.

† Orphan Drug Designation
*Fast Track Designation
**Xeris has an exclusive agreement with Tetris Pharma Limited, a subsidiary of Arecor Therapeutics plc, for the commercialization of Ogluo® in the European Economic Area, United Kingdom, and Switzerland

our values

Focus on Patients

We are committed to providing patients with therapies that improve the patient experience.

Empowered and Accountable

We make informed decisions to meet goals and commitments; and work together to help each other achieve those goals.

Do the Right Thing

We act with integrity in our work, in the relationships we build, and in how we develop our products.

Innovation

We find ways to bring unique and effective solutions to therapeutic areas with patient need.

our mission

Solutions for many therapeutic areas

We're currently developing innovative, ready-to-use solutions for various therapeutic categories to remove many associated treatment burdens and ultimately improve patients' lives.

See how we can help

leadership

We’re people people.

We’ve handpicked our team to ensure each individual’s strengths further the pursuit of our shared goal to change patients’ lives.

Get to know us
image of Paul R. Edick
Paul R. Edick
Chairman & Chief Executive Officer
Paul R. Edick joined Xeris Pharmaceuticals as Chairman and Chief Executive Officer in January 2017. Prior to Xeris, Mr. Edick was Founding Partner of 3G Advisors, a consultancy to the pharmaceutical, healthcare, and healthcare investor communities. From 2010 to 2014, Mr. Edick was the Chief Executive Officer of Durata Therapeutics (Nasdaq: DRTX), a biopharmaceutical company addressing the growing need for new antibiotics to treat infectious diseases. Durata was acquired by Actavis PLC, now Allergan PLC, in November 2014. Prior to Durata, Mr. Edick was Chief Executive Officer of Ganic Pharmaceuticals, a Warburg Pincus investment search vehicle, from 2008 to 2010. Before Ganic, Mr. Edick was Chief Executive Officer of MedPointe Healthcare, Inc., a US-based specialty pharmaceutical company, a position he assumed in 2006 after having been President of Pharmaceutical Operations since 2002. Mr. Edick led the growth of the business and the development of a clinical stage portfolio, and the company was subsequently sold to Meda AB of Sweden in 2007.

Mr. Edick also possesses extensive industry experience with leading consumer, pharmaceutical, and healthcare organizations, including Pharmacia as Group Vice President and President, Asia Pacific & Latin America Operations; and Searle Pharmaceuticals as President of Asia Pacific, Canada, and Latin America Operations and VP, Canada and Latin America Operations. He also led the national Managed Care and Marketing units, as well as the Global Pain & Inflammation unit, which included the commercialization and launch planning, for Celebrex®. In addition, Mr. Edick has also held sales, marketing, advertising, and advisory positions in Procter & Gamble, Ortho Pharmaceuticals, and The Hamilton Group.

Mr. Edick has previously served on a number of pharmaceutical and healthcare company boards, including Milestone Pharmaceuticals Inc., Iterum Therapeutics (Nasdaq: ITRM), PDL BioPharma (Nasdaq: PDLI), Neos Therapeutics (Nasdaq: NEOS), NewLink Genetics Inc. (Nasdaq: NLNK), Circassia Pharmaceuticals PLC (London: CIR.L), Sucampo Pharmaceuticals, (acquired by Mallinckrodt), Amerita Inc., and Informed Medical Communications.

Mr. Edick holds a BA in psychology from Hamilton College.
image of Beth P. Hecht
Beth P. Hecht
Chief Legal Officer and Corporate Secretary
Beth P. Hecht serves as the Chief Legal Officer and Corporate Secretary of Xeris Pharmaceuticals. She has over 25 years of experience as a corporate executive in the life science industry, most recently serving as Managing Director and Chief Legal and Administrative Officer for Auven Therapeutics, a global biotechnology and pharmaceutical private equity firm. Beth is currently a member of the Board of Directors of Iterum Therapeutics (Nasdaq: ITRM) and a member of both the Audit and Compensation Committees there. She was previously on the Board of Directors of Neos Therapeutics where she chaired the Nominating and Governance Committee.

Ms. Hecht is a graduate of Amherst College and Harvard Law School; she began her career as an attorney specializing in intellectual property and corporate transactions at Willkie Farr & Gallagher (NY) and later Kirkland & Ellis (NY). She has established and led legal, compliance, licensing, human resource, and security departments at companies including Durata Therapeutics, Sun Products, MedPointe Inc. (formerly Carter-Wallace Inc.), Warner Chilcott PLC, ChiRex Ltd., and Alpharma Inc.
image of John Shannon
John Shannon
President and Chief Operating Officer
John Shannon currently serves as the President and Chief Operating Officer of Xeris Pharmaceuticals. Mr. Shannon has 30+ years of pharmaceutical and healthcare experience with a diverse background in sales, global and US marketing, operations and manufacturing, strategic planning, and business development.

Most recently, Mr. Shannon spent two years as Chief Executive Officer for Catheter Connections, Inc., a company focused on the development and commercialization of innovative vascular access products designed to protect patients from acquiring infections during intravenous infusion therapy. Catheter Connections, Inc. was acquired by Merit Medical in January 2016.

Prior to Catheter Connections, Mr. Shannon spent three years as Chief Commercial Officer for Durata Therapeutics, a biopharmaceutical company focused on the development and commercialization of differentiated therapeutic solutions to advance patient care in infectious disease and acute illnesses. Durata was acquired by Actavis (now Allergan) in November 2014. Mr. Shannon spent 10 years (2001–2011) at Baxter Healthcare, where he was General Manager, Global Hemophilia and Global Commercial Excellence; General Manager, US Biopharmaceuticals; Vice President, Marketing US Bioscience; and Vice President, Marketing US Renal. During his time at Baxter, he led the commercialization and drove the growth of two Baxter brands, ADVATE® and GAMMAGARD®, both of which now exceed revenues of $1 billion.

Prior to coming to Baxter, Mr. Shannon was Vice President, Marketing for Caremark. Before that, he was at Searle for 10 years; there, he held several positions, most notably Executive Director, Cardiovascular Global Commercialization, in which he was responsible for the commercial development and marketing of new cardiovascular products worldwide, and Senior Director of Cox-2 Global Commercialization, in which he led the worldwide launch and global marketing of Celebrex®. In addition, he spent 7 years at Bock Pharmacal Company, where he held various positions including Sales Representative, Sales Trainer, Sales Operations, Marketing, Strategic Planning, and Business Development.

Mr. Shannon holds a BS in Biology with an emphasis in Microbiology from Western Illinois University.
image of Steve Pieper
Steve Pieper
Chief Financial Officer
Steve Pieper is the Chief Financial Officer of Xeris Pharmaceuticals, having previously served as Vice President of Finance since he joined the company in 2017. Mr Pieper brings over 20 years of experience working in the life science industry in various financial leadership roles.

Prior to Xeris, Mr. Pieper served as the CFO and COO of Catheter Connections Inc., a company focused on the development and commercialization of innovative vascular access products designed to protect patients from acquiring infections during intravenous infusion therapy. Catheter Connections, Inc. was acquired by Merit Medical in January 2016. Mr. Pieper also held the position of Director of Finance at Durata Therapeutics Inc., a biopharmaceutical company, which was acquired by Actavis (now Allergan) in November 2014. Mr. Pieper started his career in healthcare at Baxter Healthcare Corporation, where he held a variety of commercial and corporate decision support finance roles.

Mr. Pieper received an MBA from Loyola University, Chicago and BS in Finance from DePaul University.
image of Allison Wey
Allison Wey
Senior Vice President of Investor Relations and Corporate Communications
Allison Wey serves as Senior Vice President of Investor Relations and Corporate Communications of Xeris Pharmaceuticals. She brings 30+ years of experience in investor relations, corporate communications, media relations, and investment banking to Xeris leadership. Prior to joining Xeris, Ms. Wey served as Vice President, Investor Relations and Corporate Communications at Regulus Therapeutics, Durata Therapeutics, and Par Pharmaceuticals. Prior to these positions, Ms. Wey was VP, Investor Relations at Boron, LePore & Associates; Senior Vice President at Edelman Financial Worldwide; Managing Director, Financial Communications at Hill & Knowlton; and Associate Director, Equity Capital Markets at Bear, Stearns & Co. Inc. Ms. Wey is a graduate of Drake University.
image of Ken Johnson, Pharm.D.
Ken Johnson, Pharm.D.
Senior Vice President, Global Development and Medical Affairs
Dr. Ken Johnson currently serves as the Senior Vice President, Global Development and Medical Affairs of Xeris Pharmaceuticals. Dr. Johnson is responsible for leading clinical and nonclinical development, regulatory, quality and medical affairs to effectively generate high-quality scientific and clinical evidence for Xeris' products to support product approval, advance clinical education and practice, inform policy, and improve health outcomes for patients.

Dr. Johnson has more than 30 years of professional experience in the pharmaceutical industry, pharmaceutical benefits management, and academia. Dr. Johnson was most recently Executive Director, US Medical Affairs for Hospital Specialty Products at Merck. Previously, Dr. Johnson held senior management positions in Medical Affairs and Outcomes Research at Circassia Pharmaceuticals, Durata Therapeutics, Horizon Pharma, Takeda Pharmaceuticals North America, NeoPharm, Searle/Pharmacia, and Bristol-Myers Squibb. He also served as Vice President, Analytics and Outcomes Research at Caremark, working with Fortune 200 employers and other pharmacy benefit purchasers. Dr. Johnson began his professional career on the faculty at the University of Colorado School of Pharmacy, with a practice and research focus in therapeutic drug monitoring and clinical pharmacokinetics.

Dr. Johnson has established de novo Medical Affairs and Outcomes Research functions for four emerging biopharmaceutical companies. In addition, he has established and led regional Medical Affairs teams for both large global and emerging biopharmaceutical companies. Throughout his career, Dr. Johnson has consistently been recognized for his leadership, strategic thinking, collaboration, and ability to innovate across a broad range of organizations.

Dr. Johnson received his Doctor of Pharmacy from the University of Minnesota and completed a postdoctoral fellowship at the University of Tennessee Health Sciences Center. Dr. Johnson holds a number of adjunct academic appointments and is a member of several professional societies.
image of Kevin McCulloch
Kevin McCulloch
Chief Commercial Officer
Kevin McCulloch joined Xeris Pharmaceuticals in October 2018 as Senior Vice President, Global Operations and Business Development and was named Chief Commercial Officer in September, 2021. Mr. McCulloch has spent more than 30 years in the pharmaceutical and medical device industry in diverse leadership and general management roles spanning sales, marketing, and business operations for both US and international entities.

Prior to joining Xeris, Kevin was the President of Global Solutions at Hill-Rom and earlier, as Chief Business Officer for Water Street Healthcare Partners Pharmaceutical Holdings. Mr. McCulloch spent 15 years with Baxter Healthcare in successive management roles including GM/President of the Global Services, Global Fluid Systems (GFS), Infusion Systems (IS), and Fenwal business units. While the leader of GFS, he created Celerity Pharmaceuticals, one of the industry’s first R&D externalization ventures that has since successfully generated multiple new product launches. As leader of the IS business, he oversaw the acquisition and integration of Sigma International into the IS portfolio while successfully navigating the business out of a long-standing consent decree. As the President of Fenwal, a global leader in blood collection and apheresis technology, Mr. McCulloch led its successful divestiture to TPG in 2007. He started his Baxter career as a Vice President of Global Marketing in the Renal division. Prior to Baxter, Mr. McCulloch spent 9 years at GD Searle in roles of increasing responsibility in business development, marketing, and sales. He began his career as a territory sales representative with the Upjohn Company.

Mr. McCulloch holds an MBA from Northwestern University’s Kellogg School of Management and a BS in Biology from the University of Michigan.
image of Steven Prestrelski, PhD, MBA
Steven Prestrelski, PhD, MBA
Chief Scientific Officer & Cofounder
Dr. Steven Prestrelski is the Founder and Chief Scientific Officer of Xeris Pharmaceuticals. He is also the inventor of the Xeris platform technologies. Dr. Prestrelski is an internationally recognized expert in drug formulation and delivery, with over 30 years of drug development experience. Prior to joining Xeris, Dr. Prestrelski was Vice President of Pharmaceutical R&D at Amylin Pharmaceuticals. Previously, he was the Executive Director of the Bydureon® program at Amylin, leading this program from Phase 2 through global regulatory filings. Prior to Amylin, Dr. Prestrelski was Vice President, Biopharmaceuticals at PowderJect Technologies, Inc., where he pioneered the delivery of solid biopharmaceuticals. Dr. Prestrelski has also worked with Alza and Amgen in technical and management roles.

Dr. Prestrelski served on the Board of Directors of BaroFold, Inc. and on the Scientific Advisory Board of iMEDD, Inc., a Bay Area drug delivery company. Dr. Prestrelski has published over 60 invited book chapters and peer-reviewed journal articles and has over 30 issued (over 100 globally) and 40 pending patent applications in the field of drug development, formulation and delivery.

Dr. Prestrelski holds a PhD in Molecular Biophysics from the City University of New York and an MBA from the Rady School of Management at the University of California, San Diego.